United Therapeutics | UTHR - Operating Expenses

Stock Price
568.58
Daily Change
-7.21 -1.25%
Monthly
-2.06%
Yearly
86.21%
Q2 Forecast
553.25

United Therapeutics reported $5.9B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Amarin USD 51.48M 113K Dec/2025
Ardelyx USD 120.12M 14.46M Dec/2025
Baxter International USD 6.04B 2.85B Mar/2026
Bayer EUR 9.88B 452M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Insmed USD 506.24M 7.31M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Moderna USD 1.78B 242M Mar/2026
Omeros USD 59.16M 20.13M Jun/2024
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026